PNEUMOFOCUS

BULLETIN OF GAVI'S PNEUMOADIP AT JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH
PNEUMOADIP: PNEUMOCOCCAL VACCINES ACCELERATED DEVELOPMENT AND INTRODUCTION PLAN

Volume 3, No. 4 April, 2006

In This Issue
  1. ISPPD5 Overview
  2. PATH receives $75million for pneumo protein vaccine
  3. G7 endorses pilot AMC concept, but no disease named
  4. IFFIm – South Africa commits $20 million
  5. Vaccine research: 3 scientific papers
  6. Upcoming events

ISPPD5 Overview
 
Over 600 delegates from 64 countries attended the 5th International Symposium on Pneumococci and Pneumococcal Diseases in central Australia. PneumoADIP was proud to be one of the sponsors to fund 57 fellowships that supported delegates from 26 developing countries. During this five-day conference, 120 presentations and 284 posters were showcased – over 30 presentations and posters representing PneumoADIP-sponsored research and surveillance networks.

To find out about the scientific highlights, PneumoADIP session, and PneumoADIP’s quick survey results, click here or visit www.preventpneumo.org.

PneumoADIP is proud to be the first sponsor of ISPPD-6 scheduled to be held in Reykjavik, Iceland June 8-12, 2008. Save this website http://www.congress.is/ISPPD-6 for updates.

PATH receives $75million for pneumococcal protein vaccine R&D

SeattleApril 4, 2006. PATH announced its $75 million grant from The Bill & Melinda Gates Foundation to help speed the development of pneumonia protein vaccines. PATH aims to utilize the grant to work with public and private sector partners so as to identify and test vaccines tailored to pneumococcal strains prevalent in developing countries, and also to accelerate clinical testing of the drugs and encourage construction of manufacturing facilities in Africa and Asia for local production of the vaccine. For more information, visit: www.path.org.

PneumoADIP applauds the Gates Foundation for this generous and ambitious commitment to pneumococcal vaccines and looks forward to collaborating with PATH on our shared vision of preventing pneumococcal disease.



G7 endorses AMC concept – no disease named

WashingtonDCApril 21, 1006. G7 Finance Ministers convened and issued a communiqué after the meeting. Their decision on the Advance Market Commitment is as follows: “…Having endorsed the concept of the concept of a pilot Advance Market Commitments for vaccines, we call for the additional work necessary to make its launch possible in 2006…” Their next meeting is scheduled for June. The vaccine candidates under consideration for the pilot AMC are vaccines to prevent childhood pneumococcal disease, tuberculosis, malaria, HIV/AIDIS, HPV infections and rotaviral infections.


IFFIm – South Africa commits $20 million

April 6, 2006. The South African Cabinet has approved an annual contribution of $20 million to the International Financing Facility for Immunization (IFFIm) for the next 20 years. IFFIm is a GAVI initiative geared towards addressing the Millennium development Goals (MDGs), in the context of childhood diseases, including pneumococcal disease. The group of nations contributing to IFFIm continues to grow; eight countries have committed funds to IFFIm thus far.


Vaccine Research: 3 recent scientific papers

Efficiency of Laboratory Testing for Antibiotic Resistance. A recent proficiency testing survey conducted by the American Proficiency Institute (API) assessed the ability of laboratories to detect low-level penicillin resistance in a strain of S. pneumoniae. Results revealed that antimicrobial susceptibility testing practices are suboptimal in many laboratories, particularly those using disk diffusion methods which lack adequate procedures for screening for and confirming reduced susceptibility to penicillin. Additionally it was found that unapproved antimicrobial agents were used frequently for testing against S. pneumoniae. These findings underline the importance of continued educational initiatives, as well as studies to discover the reasons why laboratories fail to follow published standards, and enforcement of the use of standards by regulatory and credentialing agencies. Edson et al. Diag. Microbio. & Inf. Dis. 2006 (In Press).

Impact of PCV7 on Invasive Pneumococcal Disease. A recent study aimed to determine the rates of invasive pneumococcal disease (IPD) in young infants aged 0 to 90 days before and after PCV7 incorporation into the childhood immunization schedule in June 2000. A prospective, population-based study was conducted on infants who resided in 8 US states with active laboratory surveillance for invasive S. pneumoniae infections from July 1, 1997 to June 30, 2004. Results from this study showed that since PCV7 introduction, rates of IPD in young infants have declined significantly. Immunizing children aged 2 to 23 months has led to changes in pneumococcal carriage in infants too young to receive PCV7, indicating that this population is benefiting from the effects of herd immunity. Additionally it was found that the racial differences in the rates of IPD between white and black infants aged 0 to 90 days had been eliminated following PCV7 introduction. Continued surveillance of IPD in this and other age groups is critical to monitor this trend as well as the emergence of potential serotypes not included in PCV7. Poehling et al. JAMA. 2006 Apr; 295(14): 1668-1674.

Outcome of Pneumococcal Vaccination in Adults. A recent study investigated the impact of prior pneumococcal vaccination on in-hospital mortality and the probability of respiratory failure among hospitalized adults with community-acquired pneumonia. Individuals diagnosed with community-acquired pneumonia at 109 community and teaching hospitals in the US were identified. Immunization status, comorbidities, and outcomes were abstracted by case managers concurrently with patient care. Associations between vaccination, survival, and respiratory failure were defined using multivariable logistic regression models. Results showed that prior vaccination against pneumococcus is associated with improved survival, decreased change of respiratory failure or other complications, and decreased length of stay among hospitalized patients with community-acquired pneumonia. These observations reinforce current efforts to improve compliance with existing pneumococcal vaccination recommendations for adults. Fisman et al. Clin. Inf. Dis. 2006 Apr; 42: 1093-1101.


Upcoming Events
If you would like to share meeting dates or any other news with PneumoADIP, please contact Benedicta Kim, hekim@jhsph.edu

9TH ANNUAL CONFERENCE ON VACCINE RESEARCH
May 8-10, 2006
Baltimore, USA
http://www.nfid.org/conferences/vaccine06

33RD ANNUAL INTERNATIONAL CONFERENCE ON GLOBAL HEALTH
May 30 - June 2, 2006
Washington, DC, USA
http://www.globalhealth.org/conference/